VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression

Author's Avatar
Dec 10, 2020
Article's Main Image

Previously completed Phase 2A clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration

PR Newswire